Claims for Patent: 4,845,075

Summary for Patent: 4,845,075

Title:	Biologically active B-chain homodimers
Abstract:	Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s):	Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	06/942,161
Patent Claims:	1. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 109. 2. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 109. 3. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 101. 4. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 101. 5. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 101. 6. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 109. 7. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 15 to amino acid 109. 8. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 29 to amino acid 109. 9. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 15 to amino acid 101. 10. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 29 to amino acid 101. 11. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 1 to amino acid 101. 12. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 1 to amino acid 109. 13. A wound-healing composition comprising a therapeutically effective amount of an isolated protein according to any one of claims 1-12, and a physiologically acceptable carrier or diluent. 14. The wound-healing composition of claim 13 wherein the carrier or diluent is selected from the group consisting of albumin, saline and sterile water. 15. The wound-healing composition of claim 13, including an adjuvant. 16. The wound-healing composition of claim 15 wherein the adjuvant is selected from the group consisting of collagen, hyaluronic acid preparations, fibronectin and factor XIII. 17. A method for enhancing the wound healing process in a warm-blooded animal, comprising administering to the animal a composition according to any one of claims 13-16.

Details for Patent 4,845,075

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2006-07-04